Literature DB >> 28823713

Evaluation of HCC response to locoregional therapy: Validation of MRI-based response criteria versus explant pathology.

Sonja Gordic1, Idoia Corcuera-Solano2, Ashley Stueck3, Cecilia Besa4, Pamela Argiriadi2, Preethi Guniganti2, Michael King2, Shingo Kihira4, James Babb5, Swan Thung3, Bachir Taouli6.   

Abstract

BACKGROUND AND AIMS: This study evaluates the performance of various magnetic resonance imaging (MRI) response criteria for the prediction of complete pathologic necrosis (CPN) of hepatocellular carcinoma (HCC) post locoregional therapy (LRT) using explant pathology as a reference.
METHODS: We included 61 patients (male/female 46/15; mean age 60years) who underwent liver transplantation after LRT with transarterial chemoembolization plus radiofrequency or microwave ablation (n=56), or 90Yttrium radioembolization (n=5). MRI was performed <90days before liver transplantation. Three independent readers assessed the following criteria: RECIST, EASL, modified RECIST (mRECIST), percentage of necrosis on subtraction images, and diffusion-weighted imaging (DWI), both qualitative (signal intensity) and quantitative (apparent diffusion coefficient [ADC]). The degree of necrosis was retrospectively assessed at histopathology. Intraclass correlation coefficient (ICC) and Cohen's kappa were used to assess inter-reader agreement. Logistic regression and receiver operating characteristic analyses were used to determine imaging predictors of CPN. Pearson correlation was performed between imaging criteria and pathologic degree of tumor necrosis.
RESULTS: A total of 97HCCs (mean size 2.3±1.3cm) including 28 with CPN were evaluated. There was excellent inter-reader agreement (ICC 0.77-0.86, all methods). EASL, mRECIST, percentage of necrosis and qualitative DWI were all significant (p<0.001) predictors of CPN, while RECIST and ADC were not. EASL, mRECIST and percentage of necrosis performed similarly (area under the curves [AUCs] 0.810-0.815) while the performance of qualitative DWI was lower (AUC 0.622). Image subtraction demonstrated the strongest correlation (r=0.71-0.72, p<0.0001) with pathologic degree of tumor necrosis.
CONCLUSIONS: EASL/mRECIST criteria and image subtraction have excellent diagnostic performance for predicting CPN in HCC treated with LRT, with image subtraction correlating best with pathologic degree of tumor necrosis. Thus, MR image subtraction is recommended for assessing HCC response to LRT. LAY
SUMMARY: The assessment of hepatocellular carcinoma (HCC) tumor necrosis after locoregional therapy is essential for additional treatment planning and estimation of outcome. In this study, we assessed the performance of various magnetic resonance imaging (MRI) response criteria (RECIST, mRECIST, EASL, percentage of necrosis on subtraction images, and diffusion-weighted imaging) for the prediction of complete pathologic necrosis of HCC post locoregional therapy on liver explant. Patients who underwent liver transplantation after locoregional therapy were included in this retrospective study. All patients underwent routine liver MRI within 90days of liver transplantation. EASL/mRECIST criteria and image subtraction had excellent diagnostic performance for predicting complete pathologic necrosis in treated HCC, with image subtraction correlating best with pathologic degree of tumor necrosis.
Copyright © 2017 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Diffusion-weighted imaging; EASL criteria; Image subtraction; RECIST; mRECIST

Mesh:

Year:  2017        PMID: 28823713     DOI: 10.1016/j.jhep.2017.07.030

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  18 in total

1.  Inter-center agreement of mRECIST in transplanted patients for hepatocellular carcinoma.

Authors:  Ilaria Vicentin; Cristina Mosconi; Enrico Garanzini; Carlo Sposito; Matteo Serenari; Vincenzo Buscemi; Martina Verna; Carlo Spreafico; Rita Golfieri; Vincenzo Mazzaferro; Luciano De Carlis; Matteo Cescon; Giorgio Ercolani; Angelo Vanzulli; Alessandro Cucchetti
Journal:  Eur Radiol       Date:  2021-06-12       Impact factor: 5.315

Review 2.  Artificial Intelligence in Interventional Radiology.

Authors:  Joseph R Kallini; John M Moriarty
Journal:  Semin Intervent Radiol       Date:  2022-08-31       Impact factor: 1.780

3.  Assessment of Hepatocellular Carcinoma Response to 90Y Radioembolization Using Dynamic Contrast Material-enhanced MRI and Intravoxel Incoherent Motion Diffusion-weighted Imaging.

Authors:  Stefanie J Hectors; Sara Lewis; Paul Kennedy; Octavia Bane; Daniela Said; Maxwell Segall; Myron Schwartz; Edward Kim; Bachir Taouli
Journal:  Radiol Imaging Cancer       Date:  2020-07-24

Review 4.  A review of conventional and newer generation microwave ablation systems for hepatocellular carcinoma.

Authors:  Kento Imajo; Yuji Ogawa; Masato Yoneda; Satoru Saito; Atsushi Nakajima
Journal:  J Med Ultrason (2001)       Date:  2020-01-20       Impact factor: 1.314

5.  Mapping Drug Dose Distribution on CT Images Following Transarterial Chemoembolization with Radiopaque Drug-Eluting Beads in a Rabbit Tumor Model.

Authors:  Andrew S Mikhail; William F Pritchard; Ayele H Negussie; Venkatesh P Krishnasamy; Daniel B Amchin; John G Thompson; Paul G Wakim; David Woods; Ivane Bakhutashvili; Juan A Esparza-Trujillo; John W Karanian; Sean L Willis; Andrew L Lewis; Elliot B Levy; Bradford J Wood
Journal:  Radiology       Date:  2018-08-14       Impact factor: 11.105

6.  Histogram analysis of apparent diffusion coefficient predicts response to radiofrequency ablation in hepatocellular carcinoma.

Authors:  Xiaohong Ma; Han Ouyang; Shuang Wang; Meng Wang; Chunwu Zhou; Xinming Zhao
Journal:  Chin J Cancer Res       Date:  2019-04       Impact factor: 5.087

Review 7.  Consensus report from the 9th International Forum for Liver Magnetic Resonance Imaging: applications of gadoxetic acid-enhanced imaging.

Authors:  Dow-Mu Koh; Ahmed Ba-Ssalamah; Giuseppe Brancatelli; Ghaneh Fananapazir; M Isabel Fiel; Satoshi Goshima; Sheng-Hong Ju; Nikolaos Kartalis; Masatoshi Kudo; Jeong Min Lee; Takamichi Murakami; Max Seidensticker; Claude B Sirlin; Cher Heng Tan; Jin Wang; Jeong Hee Yoon; Mengsu Zeng; Jian Zhou; Bachir Taouli
Journal:  Eur Radiol       Date:  2021-02-01       Impact factor: 5.315

8.  Predictive Value of Early Response to Chemoradiotherapy in Advanced Esophageal Squamous Cell Carcinoma by Diffusion-Weighted MR Imaging.

Authors:  Wei Chen; Ya-Ting Wang; Lili Guo; Zhaohuan Zhu; Hai-Fei Zhou; Genji Bai
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec

Review 9.  Recent advances in liver transplantation for cancer: The future of transplant oncology.

Authors:  Phillipe Abreu; Andre Gorgen; Graziano Oldani; Taizo Hibi; Gonzalo Sapisochin
Journal:  JHEP Rep       Date:  2019-07-30

10.  Long-term outcomes of hepatocellular carcinoma that underwent chemoembolization for bridging or downstaging.

Authors:  Breno Boueri Affonso; Francisco Leonardo Galastri; Joaquim Mauricio da Motta Leal Filho; Felipe Nasser; Priscila Mina Falsarella; Rafael Noronha Cavalcante; Marcio Dias de Almeida; Guilherme Eduardo Gonçalves Felga; Leonardo Guedes Moreira Valle; Nelson Wolosker
Journal:  World J Gastroenterol       Date:  2019-10-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.